Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Billionaire James Dinan’s Top New Stock Picks For Q3

Page 1 of 2

Billionaire James Dinan founded York Capital Management, a New York-based long/short equity hedge fund, in 1991. Prior to founding York, Mr. Dinan worked at merger arbitrage firm Kellner DiLeo & Co., and before that as an investment banker at Donaldson, Lufkin & Jenrette (DLJ). At the time of its inception, York Capital had $3.6 million in investors’ money, which Mr. Dinan was able to raise primarily from his colleagues at DLJ. Since then the firm has grown significantly and now boasts around $27 billion in assets under management (AUM). York Capital Management recently filed its 13F with the SEC for the reporting period of June 30. According to the filing, York’s U.S public equity portfolio declined in value to $11.80 billion at the end of June from over $14.56 billion at the end of March. Although the fund had a diversified portfolio with representation from all sectors, stocks from the healthcare sector lead the pack, accounting for 20% of the portfolio’s value. In this article we are going to focus on the top three new stock picks of the fund, which accounted for over 12.5% of York Capital’s portfolio at the end of June.


We don’t just track the latest moves of hedge funds. We are, in fact, more interested in their 13F filings, which we use to determine the top 15 small-cap stocks held by the funds we track. We gather and share this information based on 16 years of research which showed that these 15 most popular small-cap picks have a great potential to outperform the market, beating the S&P 500 Total Return Index by nearly one percentage point per month in backtests, and easily beating the most popular large-cap picks of funds, which nonetheless get the majority of their collective capital. Why pay fees to invest in both the best and worst ideas of a particular hedge fund when you can simply mimic only the very best ideas of the best fund managers on your own? Since the beginning of forward testing in August 2012, the Insider Monkey small-cap strategy has outperformed the market every year, returning 118%,  more than two times greater returns than the S&P 500 during the same period (see more details).

James Dinan
James Dinan
York Capital Management

York Capital Management initiated a stake in Perrigo Company plc Ordinary Shares (NYSE:PRGO) during the second quarter, buying over 3.3 million shares of the company. As of June 30, this stake was worth almost $612.6 million and represented York’s largest equity holding. Shares of the Ireland-based over-the-counter drug maker ended up with gains of 11.7% for the second quarter, majorly due to the spike they had on April 8 when Mylan NV (NASDAQ:MYL) offered to buy Perrigo Company plc Ordinary Shares (NYSE:PRGO) for $29 billion in a hostile bid. Perrigo reported better-than\-expected second quarter earnings on August 5. While the Street was expecting it to report EPS of $1.96 on revenue of $1.52 billion, the company reported EPS of $2.18 on revenue of $1.53 billion. On July 28, Perrigo Company plc Ordinary Shares (NYSE:PRGO) announced that it would be acquiring Germany-based Naturwohl Pharma GmbH along with its leading dietary supplement brand, Yokebe. Daniel S. Och‘s OZ Management also initiated a stake in Perrigo Company plc Ordinary Shares (NYSE:PRGO) during the April-June period, purchasing over 3 million shares of the company.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!